Dermata Therapeutics, Inc. (DRMA)

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (25.02.2026)
DatumMeldungSchwereFilingAuszug
25.02.2026Item 5.02 — Abgang SchlüsselpersonenHOCHSEC          Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
07.05.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSECtion 13(a) of the Exchange Act. ☒         Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A
03.08.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSECt 3, 2023, is attached as Exhibit 16.1 hereto.   Item 5.02 Departure of Directors or Certain Officers; Election of Direc

Stammdaten

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Unternehmen & Branche

NameDermata Therapeutics, Inc.
TickerDRMA
CIK0001853816
BoerseUS
SektorHealthcare
IndustrieBiotechnology
SIC2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP
ISIN
TypCommon Stock
Marktkapitalisierung824.684 USD
Beta0,50
Dividendenrendite0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K-7,558,557-8.167,863,8266,223,380
2025-09-3010-Q-1,691,989-1.655,071,4103,960,102
2025-06-3010-Q-1,701,093-1.666,640,5165,614,251
2025-03-3110-Q-2,303,587-0.4510,005,0077,301,222
2024-12-3110-K-12,287,461-80.323,533,8881,561,094
2024-09-3010-Q-3,173,156-20.416,687,3444,741,228
2024-06-3010-Q-2,829,106-41.825,236,5523,318,127
2024-03-3110-Q-3,134,262-7.065,179,7563,807,990
2023-12-3110-K-7,794,690-39.997,978,6346,355,018
2023-09-3010-Q-1,719,2117,323,3836,406,566
2023-06-3010-Q-1,701,3648,712,8818,030,019
2023-03-3110-Q-2,240,1429,295,1058,088,070
2022-12-3110-K-9,610,9136,944,4886,021,854
2022-12-3110-Q-2,786,1526,944,4886,021,854
2022-09-3010-Q-2,424,5868,974,8897,470,567
2022-06-3010-Q-2,730,57311,026,4389,659,970
2022-03-3110-Q-2,786,1519,044,0157,852,519
2021-12-3110-K-7,902,47711,623,94010,107,104
2021-09-3010-Q-1,712,92013,685,78712,490,555
2021-06-3010-Q-1,331,7921,136,864-505,802

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.

Hinweis

Erweitert ×